Payment overview · 2025
General Payments
$395.15
22 reported records · 12 companies
Healthcare provider profile · identity verified
Phillip G Davis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1508852476
Verified facts
What the public records show
CMS Open Payments records show Phillip G Davis, MD received $395.15 in general payments during 2025 across 22 reported records.
Novartis Pharmaceuticals Corporation accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.93 | 24.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.43 | 19.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.40 | 12.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.93 | 8.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.85 | 5.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.54 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.48 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.09 | 4.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $16.92 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.51 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.20 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.87 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.15 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $94.93 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.41 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1478 | 437 |
| Amlodipine Besylate | Amlodipine Besylate | 1034 | 310 |
| Lisinopril | Lisinopril | 876 | 265 |
| Levothyroxine Sodium | Levothyroxine Sodium | 801 | 207 |
| Losartan Potassium | Losartan Potassium | 801 | 225 |
| Methylprednisolone | Methylprednisolone | 532 | 393 |
| Omeprazole | Omeprazole | 526 | 170 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 145 |
| Metformin Hcl | Metformin Hcl | 462 | 132 |
| Simvastatin | Simvastatin | 448 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 416 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 394 | 112 |
| Trazodone Hcl | Trazodone Hcl | 320 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 94 |
| Doxycycline Hyclate | Doxycycline Hyclate | 291 | 227 |
| Allopurinol | Allopurinol | 282 | 77 |
| Irbesartan | Irbesartan | 272 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 82 |
| Alprazolam | Alprazolam | 252 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 246 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 237 | 72 |
| Potassium Chloride | Potassium Chloride | 230 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 65 |
| Ezetimibe | Ezetimibe | 212 | 64 |
| Eliquis | Apixaban | 207 | 68 |
| Citalopram Hbr | Citalopram Hydrobromide | 205 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 101 |
| Gabapentin | Gabapentin | 197 | 64 |
| Sertraline Hcl | Sertraline Hcl | 186 | 57 |
| Torsemide | Torsemide | 175 | 55 |
| Carvedilol | Carvedilol | 166 | 51 |
| Ozempic | Semaglutide | 166 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 49 |
| Tramadol Hcl | Tramadol Hcl | 155 | 45 |
| Labetalol Hcl | Labetalol Hcl | 150 | 41 |
| Buspirone Hcl | Buspirone Hcl | 146 | 48 |
| Clonazepam | Clonazepam | 140 | 28 |
| Famotidine | Famotidine | 139 | 47 |
| Synthroid | Levothyroxine Sodium | 137 | 32 |
| Prednisone | Prednisone | 135 | 52 |
| Montelukast Sodium | Montelukast Sodium | 130 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 36 |
| Atenolol | Atenolol | 128 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 38 |
| Mounjaro | Tirzepatide | 118 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 39 |
| Warfarin Sodium | Warfarin Sodium | 115 | 19 |
| Jardiance | Empagliflozin | 113 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 108 | 90 |
| Meloxicam | Meloxicam | 105 | 31 |
| Lorazepam | Lorazepam | 101 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 25 |
| Finasteride | Finasteride | 96 | 25 |
| Metformin Hcl Er | Metformin Hcl | 90 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 74 |
| Furosemide | Furosemide | 74 | 25 |
| Mupirocin | Mupirocin | 72 | 49 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 21 |
| Spironolactone | Spironolactone | 69 | 27 |
| Clonidine | Clonidine | 68 | 13 |
| Bupropion Xl | Bupropion Hcl | 67 | 21 |
| Valacyclovir | Valacyclovir Hcl | 66 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 12 |
| Glipizide Er | Glipizide | 63 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 51 |
| Donepezil Hcl | Donepezil Hcl | 57 | 21 |
| Xarelto | Rivaroxaban | 56 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 16 |
| Ramipril | Ramipril | 54 | 16 |
| Repatha Sureclick | Evolocumab | 54 | 18 |
| Temazepam | Temazepam | 54 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 53 | 16 |
| Lovastatin | Lovastatin | 52 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Azelastine Hcl | Azelastine Hcl | 48 | 29 |
| Nifedipine Er | Nifedipine | 47 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 29 |
| Fluconazole | Fluconazole | 45 | 29 |
| Glimepiride | Glimepiride | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 12 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Azithromycin | Azithromycin | 40 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Cephalexin | Cephalexin | 38 | 24 |
| Enalapril Maleate | Enalapril Maleate | 38 | 11 |
| Nystatin | Nystatin | 38 | 22 |
| Valsartan | Valsartan | 36 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Glipizide | Glipizide | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 29 |
| Prolia | Denosumab | 31 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 16 |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Hydrocortisone | Hydrocortisone | 27 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 14 |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 12 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 22 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sotalol Af | Sotalol Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Testosterone | Testosterone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.15 · 22 records | Novartis Pharmaceuticals Corporation | ABRYSVO, Arikayce, COMIRNATY, Cologuard Collection Kit, EVENITY, JARDIANCE, LEQVIO, OTEZLA, PREVNAR 20, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error